The approval, which can be found HERE, allows for the following condition-specific claim, “Helps to reduce abdominal pain and discomfort associated with irritable bowel syndrome (IBS)”, for the company’s ibSium product.
The ingredient, also known on the market as Lynside Pro GI+ in certain countries, has demonstrated a significant effect in improving abdominal pain and discomfort in individuals with IBS, in two clinical studies (with a total of 600 volunteers with IBS) and one consumer study implemented in collaboration with prescribing physicians on over 1,160 volunteers presenting symptoms of IBS, said the company.
“As an ingredient supplier, obtaining a strong label builds trust and confidence in the quality of our products and the associated scientific research, a way for Lesaffre Human Care to reiterate its commitment to providing the highest level of service and product excellence,” said Sandrine Cuisenier, Global Marketing Manager for Lesaffre Human Care.
“Millions of people worldwide are affected by IBS, and many of them unsatisfied with their current treatment, so this claim approval will definitely have a positive impact on sales. It strengthens the position of our customers on the market by allowing end-users to better grasp the real benefits that ibSium could have on their quality of life”.
ibSium has been exclusively licensed to Medical Futures Inc., a wholly owned subsidiary of Tribute Pharmaceuticals Canada Inc. (“Tribute”), for the Canadian market. Medical Futures Inc will launch a finished product also called ibSium in Canada in the coming months, said Lesaffre.